• Users Online: 64
  • Home
  • Print this page
  • Email this page
Home Current issue Ahead of print Search About us Editorial board Archives Submit article Instructions Subscribe Contacts Login 
Year : 2023  |  Volume : 116  |  Issue : 1  |  Page : 24-27

Noninvasive method to reduce vitreous reflux following intravitreal injection

Department of Ophthalmology, Tanta University, Tanta, Egypt

Correspondence Address:
MD Raouf Gaber
Tanta University Eye Hospital, El-Gash Street, Medical Campus the Faculty of Medicine, Tanta, Gharbeya Province 31527
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ejos.ejos_93_22

Rights and Permissions

Aim To investigate the role of pre-injection antiglaucoma medications as a noninvasive method to prevent reflux following intravitreal injection (IVI). Patients and methods This single-center prospective randomized study included patients who were planned to receive an IVI of anti-vascular endothelial growth factor ranibizumab 0.05 ml for macular edema for diabetic macular edema, branch retinal vein occlusion, or choroidal neovascular membrane. Patients were randomized into five groups: no intervention (group 1), pre-injection topical brimonidine (group 2), pre-injection oral acetazolamide (Diamox) (group 3), pre-injection topical brimonidine and oral Diamox (group 4), and pre-injection paracentesis (group 5). The primary outcomes were the occurrence and degree of reflux following IVI. In addition, the evaluation of conjunctival bleb estimated the degree of reflux. Patient self-rated pain and early complications were secondary outcome measures. Results A total of 150 eyes of 150 patients were included. Vitreous reflux occurred in 13 (43%), 14 (46.7%), 19 (63.3%), six (20.0%), and four (13.3%) eyes in groups 1–5, respectively (P<0.001). Additionally, higher degrees of reflux were observed in group 1 compared with other groups. Discussion In our study, we raised the question of whether the intraocular pressure (IOP) before injection affects vitreous reflux. Therefore, we compared the effect of different antiglaucomatous medications on lowering the pre-injection IOP, and so decrease the vitreous reflux. We found that in both the paracentesis group and group of combined topical brimonidine and oral Diamox group, vitreous reflux rate is reduced significantly (P<0.001) because in these two groups, the IOP just before the injection was the lowest. Unfortunately, we could not measure the IOP after paracentesis and before the injection to avoid any risk of endophthalmitis, but we consider the paracentesis as a gold standard group for lowering IOP, although it is an invasive procedure. Interestingly, the self-rated pain rate was the same in all groups. Conclusion Pre-injection topical brimonidine combined with oral Diamox may be an effective and noninvasive method to prevent/reduce vitreous reflux following IVI.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded36    
    Comments [Add]    

Recommend this journal